Nav: Home

Hidden immune cells cause lung transplant failure

June 14, 2017

CHICAGO --- Northwestern Medicine scientists have discovered that a subset of immune cells called nonclassical monocytes (NCMs), previously unknown to reside in the lungs, play a key role in driving primary graft dysfunction (PGD), the leading cause of death after lung transplantation.

The study, published June 14 in Science Translational Medicine, also demonstrates targeting these cells could lead to novel treatments for PGD, a complication that currently impacts more than half of transplant patients.

Dr. Ankit Bharat, an assistant professor of surgery at Northwestern University Feinberg School of Medicine and a Northwestern Medicine physician, was the principal investigator of the study.

"This is a widespread, lethal problem and the biggest reason why lung transplant patients experience both early death and long-term problems. So, if you can fix PGD, you can really fix a lot about transplantation," Bharat said. "Now we know what causes it, and we can develop a treatment for it."

PGD is a severe form of lung injury that develops when the recipient's neutrophils -- white blood cells -- are recruited into the transplanted lung, initiating the inflammatory cascade and causing tissue damage. While it has been understood that neutrophils were the main effector cells seen in PGD, the mechanisms that drive their influx into the lung were unknown. Further, targeting the patient's neutrophils was not considered to be a practical strategy for treatment, given that those same cells are critical for defending the body against pathogens.

In the current study, the scientists demonstrated that NCMs hidden in the donor lung are the culprit ultimately responsible for initiating the damaging inflow of neutrophils following transplantation of that lung.

Previously, it had been thought that all donor immune cells are eradicated when the lungs are flushed with a solution prior to transplantation. But the scientists discovered that NCMs -- a type of immune cell whose structure and function have only recently been described -- are actually retained in the blood vessels of the donor lung.

After identifying these cells in the lungs for the first time, the scientists further demonstrated their fundamental role in developing PGD: NCMs activate a pathway that produces a protein called CXCL2, which acts to attract the damaging neutrophils into the lung.

The findings suggest that targeting NCMs in the donor lungs could potentially prevent the development of PGD.

"This is a clinically-relevant finding because it would likely be easy to develop a drug that kills these cells at the time of transplant," said Bharat, also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "That's a big strength of our findings: because these are donor-derived cells, you could administer those drugs to the donor lungs before transplant and prevent any potential side effects to the recipient."

The NCMs also don't seem to play a role in a recipient's ability to fight infection, the scientists found, indicating that the cells could be eradicated without weakening the immune system.

The scientists now plan to investigate developing a drug that would eliminate NCMs during transplantation. Similar therapies have already been demonstrated in their animal models.

Separately, the research also seems to suggest that these monocytes may play a broader role in other forms of lung injury beyond transplantation, including acute respiratory distress syndrome. Those findings are forthcoming in future publications.

Bharat was initially driven to investigate primary graft dysfunction after a lung transplant patient of his developed the syndrome.

"We truly believe here that if a patient develops an unsolvable problem, it should be our commitment and duty to do everything we can to take that problem to our scientific laboratories, find a cure, and then bring it back to patients," Bharat said. "Hence, while we ensure that the patients receive the best technical expertise in the field of lung transplantation -- we also want to advance the field by finding cures for such lethal problems to really make a difference in patient outcomes."

Bharat and his collaborators followed a similar path two years ago when they identified the mechanism behind hyperammonemia syndrome, a fatal disorder which affects five percent of lung transplant recipients, after it affected one of their patients. The findings, also published in Science Translational Medicine, eventually led to a treatment for a deadly syndrome that had plagued the field of lung transplantation since its inception.

"For several years since it was first identified, recipients have been dying of hyperammonemia. And now with this discovery, everyone can be effectively treated," Bharat said. "I hope that, similarly, with primary graft dysfunction we can now develop a treatment for this lethal problem."

Dr. Zhikun Zheng, a former research fellow, and Dr. Stephen Chiu, a postdoctoral fellow in the Bharat laboratory, were the first authors of the study.

The scientists demonstrated the findings using a number of sophisticated methods, including a mouse transplant model with live high-resolution single cell imaging, immunoelectron microscopy, and transcriptomic profiling using RNA-sequencing.
-end-
The paper was also co-authored by Dr. Scott Budinger, Harris Perlman, Dr. Alexander Misharin, Farida Korobova and others.

Bharat, Budinger, Perlman and Misharin are also members of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

The study was supported by National Institutes of Health (NIH) T32 DK077662 (Transplant Scientist Training Program and American Society for Transplant Surgery Resident Research Scholarship), NIH P01 AG049665, NIH P01 HL071643 (Department of the Army PR141319), and NIH HL125940 (Thoracic Surgery Foundation, American Lung Association and Society of University Surgeons.

More News at Northwestern Now

Northwestern University

Related Neutrophils Articles:

New technology promises improved treatment of inflammatory diseases
A study led by researchers at Washington State University has uncovered a potential new treatment approach for diseases associated with inflammation, including sepsis and stroke.
Common denominator that triggers asthma in favorable environments
Some so-called pro-allergic environments strongly promote the development of asthma and are responsible for the dramatic increase in the prevalence of asthma, especially in industrialized countries.
Diverse immune cell profiles and roles found in breast cancer resistance to immunotherapy
Researchers show that heterogeneity of both breast cancer cells themselves and immune composition of the tumor microenvironment are important considerations for therapy.
Nanosecond pulsed electric fields activate immune cells
Nanosecond pulsed electric fields are strong electrical pulses over a very short period of time (nanoseconds) that results in high electrical power.
Anaphylactic shock: IgG antibodies and neutrophils play an unexpected role
Teams from the Institut Pasteur, Inserm, the Paris Public Hospital Network (AP-HP), the CNRS, Paris-Sud University and Sorbonne University have successfully identified a new pathological mechanism responsible for the unexplained cases of anaphylactic shock, involving neutrophils activated by antibodies of the IgG class.
In cases when patients under anesthesia experience anaphylaxis, hyperactive immune...
A study of 86 patients reveals how drugs used for anesthesia can induce life-threatening anaphylaxis (a dangerous type of allergic reaction) through an alternative immune pathway.
Immune system discovery inspires a new barometer for inflammatory diseases
A unique discovery about the nature of neutrophils -- the most numerous white blood cells in the body -- may lead to new models for diagnosing and tracking inflammatory diseases such as cancer and osteoarthritis.
Deletion in mouse neutrophils offers clues to pathogenesis in multiple sclerosis
A mouse model called experimental autoimmune encephalomyelitis, or EAE, is used to discover disease mechanisms that may translate into treatments for patients with multiple sclerosis.
KAIST identifies the cause of sepsis-induced lung injury
A KAIST research team succeeded in visualizing pulmonary microcirculation and circulating cells in vivo with a custom-built 3D intravital lung microscopic imaging system.
Atherosclerosis: Induced cell death destabilizes plaques
Many chronic disorders arise from misdirected immune responses. A Ludwig-Maximilians-Universitaet (LMU) in Munich team led by Oliver Söhnlein now shows that neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death and that a tailored peptide inhibits the process.
More Neutrophils News and Neutrophils Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#542 Climate Doomsday
Have you heard? Climate change. We did it. And it's bad. It's going to be worse. We are already suffering the effects of it in many ways. How should we TALK about the dangers we are facing, though? Should we get people good and scared? Or give them hope? Or both? Host Bethany Brookshire talks with David Wallace-Wells and Sheril Kirschenbaum to find out. This episode is hosted by Bethany Brookshire, science writer from Science News. Related links: Why Climate Disasters Might Not Boost Public Engagement on Climate Change on The New York Times by Andrew Revkin The other kind...
Now Playing: Radiolab

An Announcement from Radiolab